ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,464 | +4.9% | 2,600 | 0.0% | 0.62% | -5.0% |
| Q2 2023 | $232,050 | -84.1% | 2,600 | -80.9% | 0.66% | -82.1% |
| Q1 2023 | $1,458,192 | -72.3% | 13,600 | -73.3% | 3.67% | -57.8% |
| Q3 2022 | $5,266,000 | +13.9% | 51,000 | +29.4% | 8.70% | +60.4% |
| Q1 2022 | $4,624,000 | -50.0% | 39,400 | -44.0% | 5.42% | +164.6% |
| Q2 2021 | $9,248,000 | -22.3% | 70,300 | -23.9% | 2.05% | -29.2% |
| Q1 2021 | $11,899,000 | -1.9% | 92,325 | +27.0% | 2.90% | +39.7% |
| Q4 2020 | $12,125,000 | +8.1% | 72,700 | 0.0% | 2.07% | -47.2% |
| Q3 2020 | $11,219,000 | +30.3% | 72,700 | +24.9% | 3.93% | -25.8% |
| Q2 2020 | $8,608,000 | +781.1% | 58,200 | +601.2% | 5.30% | +358.0% |
| Q1 2019 | $977,000 | – | 8,300 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |